利培酮治疗的分裂症患者催乳素、体脂参数与胰岛素敏感性的相关性研究

发布时间：2018-03-09 22:07

本文选题：利培酮　切入点：精神分裂症　出处：《天津医科大学》2012年硕士论文　论文类型：学位论文

【摘要】：目的：糖代谢异常在精神分裂症患者人群中的发病率高于普通人群,其发生机制尚有争论。有研究提示高催乳素血症可能与胰岛素抵抗和糖耐量降低的发生有关。本项研究初步探讨利培酮治疗的精神分裂症患者催乳素水平、体脂参数、胰岛素敏感性之间的相关性。方法：对符合入组标准的51例服用利培酮治疗的住院精神分裂症患者记录年龄、利培酮的使用剂量、精神分裂症病期,测量身高、体重、腰围、臀围,并检测空腹血糖、血清催乳素及胰岛素(FINS)。计算稳态模型的胰岛素抵抗指数(HOMA-IR)和QUICKI胰岛素敏感性指数。依据体重指数(BMI)将患者分为正常体重组(18.5≤BMI24kg/m2)和超重组(BMI≥24kg/m2),使用Pearson相关分析分析血清催乳素和胰岛素敏感性指标的相关性,并分析胰岛素敏感性指标与体脂参数的相关性。结果：催乳素与FINS、HOMA-IR、QUICKI胰岛素敏感性指数(r=0.149,P0.05；r=0.134,P0.05；r=-0.103,P0.05)均无相关性；腰臀围比(WHR)与FINS、HOMA-IR、 QUICKI胰岛素敏感性指数均无相关性(r=0.218,P0.05；r=0.185,P0.05；r=-0.196,P0.05)；脂肪含量百分比(BF%)与FINS、HOMA-IR、QUICKI胰岛素敏感性指数均无相关性(r=0.143,P0.05；r=0.125,P0.05；r=-0.246,P0.05)。体重指数(BMI)与FINS、HOMA-IR呈正相关(r=0.364,P0.01；r=0.328,P0.05)；QUICKI胰岛素敏感性指数与BMI呈负相关(r=-0.427,P0.01)。正常体重组与超重组的催乳素水平无统计学差异(t=0.597,P0.05)。超重组FINS、HOMA-IR高于正常体重组(t=2.679,P0.05；t=2.753,P0.05),超重组QUICKI胰岛素敏感性指数低于正常体重组(t=3.697,P0.01)。结论：服用利培酮治疗的精神分裂症患者催乳素水平与胰岛素抵抗无相关性；体重指数(BMI)与利培酮治疗的精神分裂症患者胰岛素敏感性指标有相关性。
[Abstract]:Objective: the incidence of abnormal glucose metabolism in patients with schizophrenia prevalence is higher than in the general population, its mechanism is still controversial. Some studies suggest that hyperprolactinemia may be associated with insulin resistance and impaired glucose tolerance was related to this study. Preliminary study of risperidone in the treatment of mental division prolactin levels in patients with body fat parameters. The correlation between insulin sensitivity.
Methods: to meet the standard set of 51 patients taking risperidone in the treatment of schizophrenia patients were recorded age, dose of risperidone, schizophrenia patients, measurement of height, weight, waist circumference, hip circumference, fasting plasma glucose, serum insulin and prolactin (FINS). Calculate the index of insulin resistance (HOMA-IR QUICKI) and insulin sensitivity index. According to body mass index (BMI) were divided into normal weight group (18.5 BMI24kg/m2) and overweight (BMI = 24kg/m2), correlation analysis of serum prolactin and insulin sensitivity index using Pearson correlation analysis, correlation analysis and insulin sensitivity index and body fat parameters.
Results: FINS, HOMA-IR, QUICKI and prolactin, insulin sensitivity index (r=0.149, P0.05; r=0.134, P0.05; r=-0.103, P0.05) had no correlation; waist hip ratio (WHR) and FINS, HOMA-IR, QUICKI and insulin sensitivity index were not correlated (r=0.218, P0.05; r= P0.05; 0.185, r=-0.196, P0.05); fat content the percentage (BF%) and FINS, HOMA-IR, QUICKI and insulin sensitivity index were not correlated (r=0.143, P0.05; r=0.125, P0.05; r=-0.246, P0.05). Body mass index (BMI) and FINS, HOMA-IR was positively correlated (r=0.364, P0.01; r=0.328, P0.05); insulin sensitivity index was negatively correlated with BMI (QUICKI r=-0.427, P0.01). No significant difference between normal weight and overweight group prolactin levels (t=0.597, P0.05). The recombinant FINS, HOMA-IR higher than the normal weight group (t=2.679, P0.05; t= 2.753, P0.05), overweight QUICKI insulin sensitivity index was lower than that of normal weight Group (t=3.697, P0.01).
Conclusion: there is no correlation between prolactin level and insulin resistance in schizophrenic patients treated with risperidone. Body mass index (BMI) is correlated with insulin sensitivity index in schizophrenic patients treated with risperidone.

【学位授予单位】：天津医科大学
【学位级别】：硕士
【学位授予年份】：2012
【分类号】：R749.3

【参考文献】